The tumor microenvironment in prostate cancer: Elucidating molecular pathways for therapy development

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 183-193

  Corn, Paul G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Castrate resistant prostate cancer; Molecular signaling; Prostate cancer; Prostate cancer therapy; Tumor microenvironment

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BMS 777607; CABOZANTINIB; CANCER VACCINE; CEDIRANIB; CILENGITIDE; DASATINIB; DENOSUMAB; DOCETAXEL; DOVITINIB; ETARACIZUMAB; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTETUMUMAB; IPILIMUMAB; IRINOTECAN; LENALIDOMIDE; OBLIMERSEN; ORTERONEL; PREDNISONE; SARACATINIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN;

ADVANCED CANCER; BONE METASTASIS; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; LYMPH NODE METASTASIS; LYMPHADENOPATHY; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYOFIBROBLAST; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84930481600     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S32839     Document Type: Review

References (106)

1. American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765-781.
4. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011;108(6):806-813.
5. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
6. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007;82(2):243-249.
7. Chi KN, Bjartell A, Dearnaley D, etal. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56(4):594-605.
8. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 2011;8(6):357-368.
9. Henshall SM, Quinn DI, Lee CS, etal. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001;61(2):423-427.
10. Massie CE, Lynch A, Ramos-Montoya A, etal. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719-2733.
11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer guidelines (version 2. 2011). 2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed November 20, 2010.
12. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12-23.
13. Mostaghel EA, Page ST, Lin DW, etal. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033-5041.
14. Montgomery RB, Mostaghel EA, Vessella R, etal. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454.
15. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res. 2010;16(4):1100-1107.
16. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100(5):671-675.
17. de Bono JS, Logothetis CJ, Molina A, etal. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
18. Tannock IF, de Wit R, Berry WR, etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
19. de Bono JS, Oudard S, Ozguroglu M, etal. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
20. Kantoff PW, Higano CS, Shore ND, etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
21. Small EJ, de Bono JS. Prostate cancer: evolution or revolution? J Clin Oncol. 2011;29(27):3595-3598.
22. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol. 2010;21(1):26-32.
23. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7(6):513-520.
24. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol. 2001;166(6):2472-2483.
25. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 2010;7(9):494-509.
26. Dudley AC, Shih SC, Cliffe AR, Hida K, Klagsbrun M. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer. 2008;99(1):118-125.
27. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005;123(6):1001-1011.
28. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 2005;65(5):1627-1630.
29. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277(6):467-471.
30. Cunha GR, Hayward SW, Dahiya R, Foster BA. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel). 1996;155(1):63-72.
31. Chung LW, Zhau HE, Ro JY. Morphologic and biochemical alterations in rat prostatic tumors induced by fetal urogenital sinus mesenchyme. Prostate. 1990;17(2):165-174.
32. Rowley DR. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 1998-1999;17(4):411-419.
33. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123(10):2229-2238.
34. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004;48(5-6):509-517.
35. Powell DW. Myofibroblasts: paracrine cells important in health and disease. Trans Am Clin Climatol Assoc. 2000;111:271-293.
36. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7(2):139-147.
37. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8(9):2912-2923.
38. Barclay WW, Woodruff RD, Hall MC, Cramer SD. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology. 2005;146(1):13-18.
39. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59(19):5002-5011.
40. Hayashi N, Cunha GR. Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res. 1991;51(18):4924-4930.
41. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res. 2007;13(4):1192-1197.
42. Bubendorf L, Schopfer A, Wagner U, etal. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol. 2000;31(5):578-583.
43. Cheng L, Bergstralh EJ, Cheville JC, etal. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998;22(12):1491-1500.
44. Pontes-Junior J, Reis ST, Dall'Oglio M, etal. Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer. J Carcinog. 2009;8:3.
45. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154(1):8-20.
46. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39(3):305-318.
47. Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer. Future Oncol. 2010;6(5):823-836.
48. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphaticmetastasis. Nat Rev Cancer. 2005;5(9):735-743.
49. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39(4):246-261.
50. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium. 2000;27(1):35-42.
51. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6(3):1140-1149.
52. Castellano D, Sepulveda JM, Garcia-Escobar I, Rodriguez-Antolin A, Sundlov A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-145.
53. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91(4):718-729.
54. Lang SH, Miller WR, Habib FK. Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow. Prostate. 1995;27(5):287-293.
55. Blaszczyk N, Masri BA, Mawji NR, etal. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res. 2004;10(5):1860-1869.
56. Li Y, Sikes RA, Malaeb BS, etal. Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models. Urol Oncol. 2011;29(6):802-808.
57. Sung SY, Hsieh CL, Law A, etal. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008;68(23):9996-10003.
58. Lu Y, Zhang J, Dai J, etal. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis. 2004;21(5):399-408.
59. Reichert JC, Quent VM, Burke LJ, Stansfield SH, Clements JA, Hutmacher DW. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials. 2010;31(31):7928-7936.
60. Parker C, Heinrich D, O'Sullivan JM, etal. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Paper presented at: 2011 European Multidisciplinary Cancer Congress; September 24-27, 2011; Stockholm, Sweden.
61. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1(1):46-54.
62. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer. 2008;15(3):657-664.
63. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18(5):516-523.
64. Thalmann GN, Rhee H, Sikes RA, etal. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol. 2010;58(1):162-171.
65. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis-new insights into epithelial-stromal interactions. Cancer Cell. 2007;12(6):495-497.
66. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 2009;5(9):1403-1413.
67. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res. 2006;12(6):1665-1671.
68. Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011;14(3):192-205.
69. Sternberg CN, Dumez H, Van Poppel H, etal. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20(7):1264-1269.
70. Carducci MA, Saad F, Abrahamsson PA, etal. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959-1966.
71. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010;3:39-51.
72. AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer [press release]. London: AstraZeneca; February 7, 2011.
73. Fizazi K, Carducci M, Smith M, etal. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.
74. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007;18(11):1765-1773.
75. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009;103(4):434-440.
76. Mendiratta P, Mostaghel E, Guinney J, etal. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009;27(12):2022-2029.
77. Araujo JC, Mathew P, Armstrong AJ, etal. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2study. Cancer. 2012;118(1):63-71.
78. Bristol-Myers Squibb. Randomized study comparing docetaxel plus dasatinib to docetaxel plus placebo in castration-resistant prostate cancer (READY). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated April 30, 2012]. Available from: http://clinicaltrials.gov/show/NCT00744497. NLM Identifier: NCT00744497. Accessed December 21, 2011.
79. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer. 2005;41(6):846-857.
80. Bhowmick NA, Chytil A, Plieth D, etal. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848-851.
81. Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets. 2009;13(2):227-234.
82. Verona EV, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh IT, Sun LZ. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res. 2007;67(12):5737-5746.
83. Song K, Wang H, Krebs TL, Kim SJ, Danielpour D. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res. 2008;68(19):8173-8182.
84. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839-849.
85. Mackay HJ, Buckanovich RJ, Hirte H, etal. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol. 2012;125(1):136-140.
86. Colombo N, Mangili G, Mammoliti S, etal. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012;125(1):42-47.
87. de Groot JF, Lamborn KR, Chang SM, etal. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19):2689-2695.
88. Twardowski P, Stadler WM, Frankel P, etal. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923-926.
89. Sanofi-Aventis; Regeneron Pharmaceuticals. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine. 2007 [updated April 30, 2012]. Available from: http://clinicaltrials.gov/show/NCT00519285. NLM Identifier: NCT00519285. Accessed December 21, 2011.
90. Van Cutsem E, Tabernero J, Lakomy R, etal. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial (EFC10262-VELOUR) [abstract]. Ann Oncol. 2011;22(Suppl 5):v18.
91. Van Cutsem E, Prenen H, Guillen-Ponce C, etal. A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6in patients with metastatic colorectal cancer. Paper presented at: 2011 European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, Sweden.
92. Adelerg D, Karakunnel JJ, Gulley JL, etal. A phase II study of cediranib in post-docetaxel castration-resistant prostate cancer. Paper presented at: American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
93. Dalgleish A, Galustian C. The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol. 2010;6(9):1479-1484.
94. Celgene to discontinue docetaxel and prednisone plus lenalidomide phase III trial on CRPC [press release]. Boudry: Celgene International Sarl; November 23, 2011.
95. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129(5):1177-1180.
96. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12(12):3657-3660.
97. Jiang WG. Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies. Curr Oncol. 2007;14(2):66-69.
98. Cao B, Su Y, Oskarsson M, etal. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A. 2001;98(13):7443-7448.
99. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther. 2010;9(6):1554-1561.
100. Hussain M, Smith MR, Sweeney C, etal. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract]. J Clin Oncol. 2011;29 Suppl:4516.
101. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol. 2011;8(9):551-561.
102. Bander NH, Yao D, Liu H, etal. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and-gamma. Prostate. 1997;33(4):233-239.
103. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220-227.
104. Mercader M, Bodner BK, Moser MT, etal. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001;98(25):14565-14570.
105. MD Anderson Cancer Center; Bristol-Myers Squibb. Ipilimumab + androgen deprivation therapy in prostate cancer. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine. 2011 [updated April 11, 2012]. Available from: http://clinicaltrials.gov/show/NCT01377389. NLM Identifier: NCT01377389. Accessed December 21, 2011.
106. OHSU Knight Cancer Institute; National Cancer Institute. Ipilimumab in combination with androgen suppression therapy in treating patients with metastatic hormone-resistant prostate cancer. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine. 2011 [updated March 22, 2012]. Available from: http://clinicaltrials.gov/show/NCT01498978. NLM Identifier: NCT01498978. Accessed December 21, 2011.